Navidea Biopharmaceuticals, Inc.
| NYSE MKT: NAVB
Navidea Biopharmaceuticals, Inc. develops and commercializes precision diagnostics and radiopharmaceutical agents, which are intended to improve diagnostic accuracy, clinical decision-making and patient care. Its current radiopharmaceutical development programs include Lymphoseek, AZD4694 and RIGScan agents, which are used in treating various tumor cancers. The company's primary focus in to improve surgery outcomes by using market-leading gamma detection devices in combination with radiopharmaceutical agents. The company was founded in 1983 and is headquartered in Dublin, OH.